Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.48 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875421 | 0.77 | TEAD1 (0.46) | EPHX2TEAD1CES2CES1GAA | |
| SCHEMBL14161881 | 0.77 | TEAD1 (0.46) | EPHX2TEAD1CES2CES1GAA | |
| SCHEMBL7647671 | 0.75 | RAB9A (0.59) | TEAD1CES2CES1SLC6A5 | |
| SCHEMBL4882387 | 0.73 | EPHX2 (0.69) | EPHX2TEAD1SLC6A5 | |
| SCHEMBL13754009 | 0.71 | MEN1 (0.51) | ALDH1A1POLBTDP1CCNA2CDK2 | |
| SCHEMBL4880073 | 0.71 | LMNA (0.68) | EPHX2ALDH1A1GAA | |
| SCHEMBL16570428 | 0.70 | EPHX2 (0.72) | EPHX2ALDH1A1 | |
| SCHEMBL10441841 | 0.70 | CES2 (0.67) | EPHX2CES2CES1 | |
| SCHEMBL385370 | 0.69 | LMNA (0.60) | CES2CES1ALDH1A1TDP1 | |
| SCHEMBL7652620 | 0.69 | NPC1 (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008073623-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885TEAD1 1487/4885CES2 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.